Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate
Raises Hopes Of Challenging Abecma And Carvykti
Executive Summary
While a cloud hangs over the future of its CD19-targeting allogeneic candidate, Allogene points to preclinical potential of superior efficacy for ALLO-715.
You may also be interested in...
SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.
Speculation Grows On Potential Big Pharma Buyout Of Mirati
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.